Welcome to our dedicated page for Akso Health Group SEC filings (Ticker: AHG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akso Health Group filings document the disclosures of a foreign private issuer that files annual reports on Form 20-F and furnishes current reports on Form 6-K. Recent filings include unaudited interim consolidated financial statements, operating and financial review materials, and incorporation of those materials into registration statements on Form S-8 and Form F-3.
The company’s regulatory reports also cover board and committee governance, including changes to independent director roles on the audit, compensation, and nominating and corporate governance committees. The filings frame Akso Health’s public-company reporting around financial position, operating review, capital-market registrations, and governance disclosures.
Akso Health Group (AHG) presents a wide-ranging annual report describing a company transitioning from prior microlending activities into an "Internet+healthcare" and social e-commerce model while pursuing medical device sales, online consultations, community health stations and cancer therapy centers. The company reported higher sales and marketing spend of US$168,421 for the year ended March 31, 2024 versus US$6,661 the prior year driven by brand-building for new businesses, and a reduction in general and administrative expenses to US$8.6 million (down 44.7% from US$15.5 million) primarily due to lower provisions for uncollected receivables. The report discloses net income from discontinued operations of US$11.84 million and highlights significant operational and regulatory risk factors, including dependence on suppliers, client concentration, cybersecurity and data-protection obligations, heavy PRC regulatory oversight, potential HFCAA-related listing risks, lack of business insurance, and material uncertainties around approvals, licensing and cross-border capital flows.